AG
RETA

Aperio Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Aperio Group’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1.02M Buy
8,287
+2,324
+39% +$305K ﹤0.01% 1574
2020
Q3 		$581K Buy
5,963
+1,494
+33% +$187K ﹤0.01% 1740
2020
Q2 		$697K Buy
4,469
+578
+15% +$87.9K ﹤0.01% 1595
2020
Q1 		$562K Buy
3,891
+1,363
+54% +$263K ﹤0.01% 1587
2019
Q4 		$517K Buy
+2,528
New +$461K ﹤0.01% 1778
2019
Q3 		– Sell
-2,316
Closed -$219K – 2853
2019
Q2 		$219K Buy
+2,316
New +$200K ﹤0.01% 2146

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Aperio Group's RETA Position: Q4 2020 in Review

Aperio Group increased its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 39% in Q4 2020, buying an estimated $305K and bringing the position to 8,287 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Aperio Group first reported a position in RETA in Q2 2019 and has held it in 6 quarters since. 202 funds tracked by Wall St. Rank hold RETA as of Q4 2020.

  • Aperio Group held 8,287 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $1.02M as of Q4 2020.
  • Aperio Group bought 2,324 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2020, an estimated $305K.
  • Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1574 holding.
  • Aperio Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and has held it in 6 quarters since.
  • 202 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.